GWP42003-P
ApprovedWithdrawn 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Lennox-Gastaut Syndrome
Conditions
Lennox-Gastaut Syndrome
Trial Timeline
Oct 1, 2020 → Dec 1, 2021
NCT ID
NCT04133480About GWP42003-P
GWP42003-P is a approved stage product being developed by Jazz Pharmaceuticals for Lennox-Gastaut Syndrome. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04133480. Target conditions include Lennox-Gastaut Syndrome.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04485104 | Phase 3 | Terminated |
| NCT04133480 | Approved | Withdrawn |
| NCT04252586 | Phase 3 | Terminated |
| NCT02954887 | Phase 3 | Completed |
| NCT02953548 | Phase 3 | Completed |
| NCT02607904 | Phase 2 | Completed |
| NCT02544750 | Phase 3 | Completed |
Competing Products
6 competing products in Lennox-Gastaut Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Placebo + Perampanel | Eisai | Phase 3 | 77 |
| Rufinamide | Eisai | Pre-clinical | 23 |
| Rufinamide (E2080) + Placebo | Eisai | Phase 3 | 77 |
| Rufinamide | Eisai | Phase 3 | 77 |
| Rufinamide + Any other approved Antiepileptic Drug | Eisai | Phase 3 | 77 |
| Clobazam | Lundbeck | Phase 3 | 74 |